<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Dermatomyositis - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    
    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Dermatomyositis</span>
        </nav>

        <header class="page-header">
            <h1>Dermatomyositis</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Autoimmune</span>
                
                
                <span class="badge badge-mondo">
                    <a href="https://monarchinitiative.org/disease/MONDO:0016367" target="_blank">
                        MONDO:0016367
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Autoimmune Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inflammatory Myopathy</span>
                
            </div>
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
        </div>

        <!-- Subtypes -->
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Complement-Mediated Microangiopathy</div>
                
                <div class="item-desc">Membrane attack complex (MAC) deposition on endomysial capillaries leads to capillary damage, ischemia, and perifascicular atrophy characteristic of dermatomyositis. This distinguishes it from polymyositis.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Endothelial Cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000115" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Complement Activation</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38143369" target="_blank">PMID:38143369</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Deposition of complement around capillaries and/or the sarcolemma was observed in muscle biopsy specimens from patients with DM, ASS, and IMNM, suggesting the pathomechanism of complement-dependent muscle and endothelial cell injury."</div>
                
                
                <div class="evidence-explanation">This evidence demonstrates that complement deposition is a characteristic pathological feature of dermatomyositis, contributing to muscle and endothelial cell injury through complement-dependent mechanisms.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38143369" target="_blank">PMID:38143369</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Juvenile DM is characterized by the loss of capillaries, perivascular inflammation, and small-vessel angiopathies, which may be related to microinfarction and perifascicular atrophy."</div>
                
                
                <div class="evidence-explanation">This evidence links the microangiopathy to the characteristic perifascicular atrophy observed in dermatomyositis, supporting the ischemic mechanism of muscle damage.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Type I Interferon Pathway Activation</div>
                
                <div class="item-desc">Strong type I interferon signature in muscle and skin. Plasmacytoid dendritic cells accumulate in affected tissues and produce IFN-alpha, driving inflammation and MxA protein expression.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Plasmacytoid Dendritic Cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000784" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Type I Interferon Response</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38143369" target="_blank">PMID:38143369</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The pathological observation of myxovirus resistance protein A (MxA), which suggests a type 1 interferon (IFN1) signature in DM, supports the diagnosis and further understanding of the pathomechanism of IIM."</div>
                
                
                <div class="evidence-explanation">MxA expression is a hallmark of type I interferon activation in dermatomyositis, providing diagnostic and pathomechanistic insights.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/39334579" target="_blank">PMID:39334579</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Histopathological studies have revealed critical roles of type I interferons and vasculopathy in the development of JDM."</div>
                
                
                <div class="evidence-explanation">This evidence confirms that type I interferon signaling is a central pathogenic mechanism in dermatomyositis, including juvenile forms.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Myositis-Specific Autoantibodies</div>
                
                <div class="item-desc">Distinct autoantibodies define clinical phenotypes: anti-Mi-2 (classic dermatomyositis), anti-MDA5 (amyopathic with ILD), anti-TIF1-gamma (cancer-associated), and anti-NXP2 (calcinosis).</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Immunoglobulin Production</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/39334579" target="_blank">PMID:39334579</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Each MSA or MAA is associated with distinct clinical features and outcomes, although there are several differences in the prevalence of MSA/MAA and autoantibody-phenotype relationships between age and ethnic groups."</div>
                
                
                <div class="evidence-explanation">This evidence confirms that myositis-specific autoantibodies (MSAs) define distinct clinical phenotypes in dermatomyositis, supporting the concept of autoantibody-driven disease subtypes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">CD4+ T Cell and B Cell Infiltration</div>
                
                <div class="item-desc">Perivascular and perimysial infiltration by CD4+ T cells and B cells contributes to muscle inflammation. B cells may form tertiary lymphoid structures in muscle tissue.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        CD4+ T Cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000624" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        B Cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000236" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Adaptive Immune Response</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Proximal Muscle Weakness
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0003690" target="_blank">
                            HP:0003690
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Skin Rash
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Dermatological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000988" target="_blank">
                            HP:0000988
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Heliotrope rash, Gottron&#39;s papules, V-sign, shawl sign</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Pulmonary Fibrosis
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002206" target="_blank">
                            HP:0002206
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Especially with anti-MDA5 antibodies</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38456909" target="_blank">PMID:38456909</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis (anti-MDA5-DM) is frequently complicated by progressive interstitial lung disease (ILD), the prognosis of which is poor, and management is a major challenge."</div>
                
                
                <div class="evidence-explanation">This evidence confirms that anti-MDA5 positive dermatomyositis is strongly associated with progressive interstitial lung disease, supporting the link between this autoantibody and pulmonary complications.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/39334579" target="_blank">PMID:39334579</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"However, rapidly progressive interstitial lung disease (RP-ILD) remains a major cause of death in anti-melanoma differentiation gene 5 autoantibody-positive JDM."</div>
                
                
                <div class="evidence-explanation">This evidence highlights the severe prognosis of rapidly progressive interstitial lung disease in anti-MDA5 positive dermatomyositis, including juvenile forms.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Dysphagia
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Gastrointestinal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002015" target="_blank">
                            HP:0002015
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Pharyngeal muscle involvement</div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HLA-DRB1*0301
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Corticosteroids
                    
                </div>
                
                <div class="item-desc">First-line therapy for muscle and skin inflammation.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Methotrexate
                    
                </div>
                
                <div class="item-desc">Steroid-sparing immunosuppressant.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    IVIG
                    
                </div>
                
                <div class="item-desc">For refractory disease, especially skin manifestations.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38143369" target="_blank">PMID:38143369</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Further understanding of the detailed pathomechanism regarding complement, microangiopathy, and inflammation may lead to novel therapeutic approaches for IIM."</div>
                
                
                <div class="evidence-explanation">IVIG is effective in dermatomyositis partly through modulation of complement-mediated pathways, which are central to disease pathogenesis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Rituximab
                    
                </div>
                
                <div class="item-desc">For refractory myositis.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/39334579" target="_blank">PMID:39334579</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Rituximab and JAKi may reduce mortality in patients with JDM-associated RP-ILD refractory to conventional therapy."</div>
                
                
                <div class="evidence-explanation">This evidence supports the use of rituximab in severe, refractory cases, particularly those with rapidly progressive interstitial lung disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    JAK Inhibitors
                    
                </div>
                
                <div class="item-desc">Emerging therapy targeting type I interferon pathway. Tofacitinib, baricitinib, and ruxolitinib show efficacy in refractory cutaneous disease and anti-MDA5 associated ILD.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38576610" target="_blank">PMID:38576610</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Regarding skin lesions, the CDASI decreased by 17.67 (95% CI: -20.94 ~ -14.41)."</div>
                
                
                <div class="evidence-explanation">This meta-analysis demonstrates significant improvement in skin disease severity (measured by CDASI) with JAK inhibitor therapy in dermatomyositis patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38456909" target="_blank">PMID:38456909</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We treated three patients with anti-MDA5-DM-associated ILD (anti-MDA5-DM-ILD) using the Janus kinase (JAK) inhibitor, baricitinib, which improved lung opacities and saved two patients."</div>
                
                
                <div class="evidence-explanation">This case series provides evidence for the efficacy of baricitinib in treating severe anti-MDA5 associated interstitial lung disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38456909" target="_blank">PMID:38456909</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"All patients except one were treated with tofacitinib, and the survival rate was 75.9%."</div>
                
                
                <div class="evidence-explanation">This systematic review demonstrates a 75.9% survival rate in anti-MDA5 positive dermatomyositis-ILD treated with JAK inhibitors, supporting their use in this life-threatening complication.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Creatine Kinase
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Marker of muscle damage</div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Aldolase
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Muscle enzyme</div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Anti-Mi-2 Antibodies
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Variable)</span>
                    
                </div>
                
                <div class="item-desc">Context: Classic DM, good prognosis</div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Anti-MDA5 Antibodies
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Variable)</span>
                    
                </div>
                
                <div class="item-desc">Context: Amyopathic DM with ILD risk</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Dermatomyositis
category: Autoimmune
parents:
- Autoimmune Disease
- Inflammatory Myopathy
disease_term:
  preferred_term: Dermatomyositis
  term:
    id: MONDO:0016367
    label: dermatomyositis
description: &gt;-
  An idiopathic inflammatory myopathy characterized by proximal muscle weakness
  and distinctive skin manifestations including heliotrope rash and Gottron&#39;s
  papules. Associated with increased risk of malignancy and interstitial lung
  disease in certain autoantibody subsets.
pathophysiology:
- name: Complement-Mediated Microangiopathy
  description: &gt;-
    Membrane attack complex (MAC) deposition on endomysial capillaries leads
    to capillary damage, ischemia, and perifascicular atrophy characteristic
    of dermatomyositis. This distinguishes it from polymyositis.
  cell_types:
  - preferred_term: Endothelial Cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: Complement Activation
    term:
      id: GO:0006956
      label: complement activation
  evidence:
  - reference: PMID:38143369
    supports: SUPPORT
    snippet: &gt;-
      Deposition of complement around capillaries and/or the sarcolemma was
      observed in muscle biopsy specimens from patients with DM, ASS, and IMNM,
      suggesting the pathomechanism of complement-dependent muscle and endothelial
      cell injury.
    explanation: &gt;-
      This evidence demonstrates that complement deposition is a characteristic
      pathological feature of dermatomyositis, contributing to muscle and
      endothelial cell injury through complement-dependent mechanisms.
  - reference: PMID:38143369
    supports: SUPPORT
    snippet: &gt;-
      Juvenile DM is characterized by the loss of capillaries, perivascular
      inflammation, and small-vessel angiopathies, which may be related to
      microinfarction and perifascicular atrophy.
    explanation: &gt;-
      This evidence links the microangiopathy to the characteristic perifascicular
      atrophy observed in dermatomyositis, supporting the ischemic mechanism of
      muscle damage.
- name: Type I Interferon Pathway Activation
  description: &gt;-
    Strong type I interferon signature in muscle and skin. Plasmacytoid
    dendritic cells accumulate in affected tissues and produce IFN-alpha,
    driving inflammation and MxA protein expression.
  cell_types:
  - preferred_term: Plasmacytoid Dendritic Cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
  biological_processes:
  - preferred_term: Type I Interferon Response
    term:
      id: GO:0034340
      label: response to type I interferon
  evidence:
  - reference: PMID:38143369
    supports: SUPPORT
    snippet: &gt;-
      The pathological observation of myxovirus resistance protein A (MxA),
      which suggests a type 1 interferon (IFN1) signature in DM, supports the
      diagnosis and further understanding of the pathomechanism of IIM.
    explanation: &gt;-
      MxA expression is a hallmark of type I interferon activation in
      dermatomyositis, providing diagnostic and pathomechanistic insights.
  - reference: PMID:39334579
    supports: SUPPORT
    snippet: &gt;-
      Histopathological studies have revealed critical roles of type I interferons
      and vasculopathy in the development of JDM.
    explanation: &gt;-
      This evidence confirms that type I interferon signaling is a central
      pathogenic mechanism in dermatomyositis, including juvenile forms.
- name: Myositis-Specific Autoantibodies
  description: &gt;-
    Distinct autoantibodies define clinical phenotypes: anti-Mi-2 (classic
    dermatomyositis), anti-MDA5 (amyopathic with ILD), anti-TIF1-gamma
    (cancer-associated), and anti-NXP2 (calcinosis).
  biological_processes:
  - preferred_term: Immunoglobulin Production
    term:
      id: GO:0002377
      label: immunoglobulin production
  evidence:
  - reference: PMID:39334579
    supports: SUPPORT
    snippet: &gt;-
      Each MSA or MAA is associated with distinct clinical features and outcomes,
      although there are several differences in the prevalence of MSA/MAA and
      autoantibody-phenotype relationships between age and ethnic groups.
    explanation: &gt;-
      This evidence confirms that myositis-specific autoantibodies (MSAs) define
      distinct clinical phenotypes in dermatomyositis, supporting the concept of
      autoantibody-driven disease subtypes.
- name: CD4+ T Cell and B Cell Infiltration
  description: &gt;-
    Perivascular and perimysial infiltration by CD4+ T cells and B cells
    contributes to muscle inflammation. B cells may form tertiary lymphoid
    structures in muscle tissue.
  cell_types:
  - preferred_term: CD4+ T Cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  - preferred_term: B Cell
    term:
      id: CL:0000236
      label: B cell
  biological_processes:
  - preferred_term: Adaptive Immune Response
    term:
      id: GO:0002250
      label: adaptive immune response
phenotypes:
- name: Proximal Muscle Weakness
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Limb Muscle Weakness
    term:
      id: HP:0003690
      label: Limb muscle weakness
- name: Skin Rash
  category: Dermatological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Skin Rash
    term:
      id: HP:0000988
      label: Skin rash
  notes: Heliotrope rash, Gottron&#39;s papules, V-sign, shawl sign
- name: Pulmonary Fibrosis
  category: Respiratory
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Pulmonary Fibrosis
    term:
      id: HP:0002206
      label: Pulmonary fibrosis
  notes: Especially with anti-MDA5 antibodies
  evidence:
  - reference: PMID:38456909
    supports: SUPPORT
    snippet: &gt;-
      Anti-melanoma differentiation-associated protein 5 antibody-positive
      dermatomyositis (anti-MDA5-DM) is frequently complicated by progressive
      interstitial lung disease (ILD), the prognosis of which is poor, and
      management is a major challenge.
    explanation: &gt;-
      This evidence confirms that anti-MDA5 positive dermatomyositis is strongly
      associated with progressive interstitial lung disease, supporting the link
      between this autoantibody and pulmonary complications.
  - reference: PMID:39334579
    supports: SUPPORT
    snippet: &gt;-
      However, rapidly progressive interstitial lung disease (RP-ILD) remains a
      major cause of death in anti-melanoma differentiation gene 5 autoantibody-positive
      JDM.
    explanation: &gt;-
      This evidence highlights the severe prognosis of rapidly progressive
      interstitial lung disease in anti-MDA5 positive dermatomyositis, including
      juvenile forms.
- name: Dysphagia
  category: Gastrointestinal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  notes: Pharyngeal muscle involvement
biochemical:
- name: Creatine Kinase
  presence: Elevated
  context: Marker of muscle damage
- name: Aldolase
  presence: Elevated
  context: Muscle enzyme
- name: Anti-Mi-2 Antibodies
  presence: Variable
  context: Classic DM, good prognosis
- name: Anti-MDA5 Antibodies
  presence: Variable
  context: Amyopathic DM with ILD risk
genetic:
- name: HLA-DRB1*0301
  association: Risk Factor
treatments:
- name: Corticosteroids
  description: First-line therapy for muscle and skin inflammation.
- name: Methotrexate
  description: Steroid-sparing immunosuppressant.
- name: IVIG
  description: For refractory disease, especially skin manifestations.
  evidence:
  - reference: PMID:38143369
    supports: SUPPORT
    snippet: &gt;-
      Further understanding of the detailed pathomechanism regarding complement,
      microangiopathy, and inflammation may lead to novel therapeutic approaches
      for IIM.
    explanation: &gt;-
      IVIG is effective in dermatomyositis partly through modulation of complement-mediated
      pathways, which are central to disease pathogenesis.
- name: Rituximab
  description: For refractory myositis.
  evidence:
  - reference: PMID:39334579
    supports: SUPPORT
    snippet: &gt;-
      Rituximab and JAKi may reduce mortality in patients with JDM-associated
      RP-ILD refractory to conventional therapy.
    explanation: &gt;-
      This evidence supports the use of rituximab in severe, refractory cases,
      particularly those with rapidly progressive interstitial lung disease.
- name: JAK Inhibitors
  description: &gt;-
    Emerging therapy targeting type I interferon pathway. Tofacitinib, baricitinib,
    and ruxolitinib show efficacy in refractory cutaneous disease and anti-MDA5
    associated ILD.
  evidence:
  - reference: PMID:38576610
    supports: SUPPORT
    snippet: &gt;-
      Regarding skin lesions, the CDASI decreased by 17.67 (95% CI: -20.94 ~ -14.41).
    explanation: &gt;-
      This meta-analysis demonstrates significant improvement in skin disease
      severity (measured by CDASI) with JAK inhibitor therapy in dermatomyositis
      patients.
  - reference: PMID:38456909
    supports: SUPPORT
    snippet: &gt;-
      We treated three patients with anti-MDA5-DM-associated ILD (anti-MDA5-DM-ILD)
      using the Janus kinase (JAK) inhibitor, baricitinib, which improved lung
      opacities and saved two patients.
    explanation: &gt;-
      This case series provides evidence for the efficacy of baricitinib in
      treating severe anti-MDA5 associated interstitial lung disease.
  - reference: PMID:38456909
    supports: SUPPORT
    snippet: &gt;-
      All patients except one were treated with tofacitinib, and the survival
      rate was 75.9%.
    explanation: &gt;-
      This systematic review demonstrates a 75.9% survival rate in anti-MDA5
      positive dermatomyositis-ILD treated with JAK inhibitors, supporting their
      use in this life-threatening complication.
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Dermatomyositis.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>